KODK

Eastman Kodak Company: Q1 1997 Financial Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 1997. Eastman Kodak Company operates primarily in Consumer and Commercial Imaging segments. The quarter was significantly impacted by the acquisition of Wang Laboratories' software unit on March 17, 1997, and the prior sale of the Office Imaging business.

Key Financial Metrics

Note: Total Debt calculated as Short-term borrowings ($557M) + Long-term borrowings ($577M).

Material Changes vs. Prior Period

• Revenue Decline: Sales decreased 8% to $3,133 million, primarily due to the divestiture of the Office Imaging business. Excluding this sale, sales would have increased 2%.
• Profitability Drop: Net earnings fell 46% to $149 million. This decline was driven by a one-time pre-tax charge of $186 million for in-process research and development (R&D) associated with the Wang Laboratories acquisition.
• Segment Performance:
  • Consumer Imaging: Sales increased 3% (driven by U.S. growth of 12%), but operating earnings dropped 10% due to lower selling prices and currency effects.
  • Commercial Imaging: Sales decreased 16% due to the Office Imaging divestiture. Operating earnings fell 77% largely due to the $186M R&D charge; excluding this charge, earnings were essentially level.
• Cash Flow: Operating cash flow turned negative ($5 million used) compared to $424 million provided in the prior year, due to working capital changes (inventory build-up and liability reductions) and the acquisition costs.

Guidance, Outlook, and Risks

• Stock Repurchase Program: The company announced a $2 billion stock repurchase program in April 1996. As of March 31, 1997, $971 million had been repurchased. The remainder is expected to be completed over the next one to two years.
• Acquisition Impact: The Wang Laboratories acquisition added workflow and document management software capabilities. The $186 million R&D charge was expensed immediately as the technology had not reached feasibility.
• Liquidity: Cash reserves decreased from $1,796 million to $872 million (including marketable securities) due to the stock buyback and acquisition. Management states available cash and operations will fund the remainder of the buyback program.
• Legal Contingencies:
  • Antitrust: A pending appeal regarding a 1995 jury verdict in the Image Technical Service, Inc. v. Eastman Kodak Company case, which resulted in a trebled verdict of approximately $71.8 million. Three similar cases are also pending.
  • Environmental: Designated as a potentially responsible party at approximately 20 Superfund sites; management does not expect future costs to be material.
• Accounting Changes: The company plans to adopt SFAS No. 128 (Earnings Per Share) in Q4 1997, which will require restating historical EPS data.

Investor Verification Checklist

• Verify the sustainability of Consumer Imaging growth (12% U.S. sales increase) against the backdrop of lower effective selling prices.
• Confirm the timeline and funding source for the remaining $1 billion of the stock repurchase program given the significant cash outflow in Q1.
• Monitor the status of the antitrust appeal in the ITS v. Kodak case and the three related pending lawsuits.
• Assess the integration progress and revenue contribution of the Wang Laboratories software unit in subsequent quarters.
• Review the impact of foreign currency exchange rates on international sales, which negatively affected both Consumer and Commercial segments.